Novel Cellular Probe Technologies for Screening Anti-Viral Therapeutic Candidates on Multiple Platforms

COVID-19 has demonstrated that emerging viruses present acute threats to human health. During rapidly spreading epidemics, affected individuals need to be treated urgently with antivirals and agents that intercept tissue damage. The epidemic has highlighted the need for rapid and effective screening of both novel and repurposed agents so that promising therapeutics can enter the path to the clinic.

For the last 20 years, BioStatus has been inventing, developing and manufacturing innovative reagents and molecular probes for cell-based analysis, imaging and screening applications in biomedicine. We supply customers all over the world to the ISO 9001:2015 quality standard. As an innovative company, we seek to make a positive impact in the area that we can best serve – in our case, the discovery pipeline for new treatments.

Our project aim is to rapidly exploit a new family of probes and novel combinations of our existing probes. Our fluorescent reagents are chemically designed to enter cells and reveal changes brought about by a viral attack. Our patented technologies allow researchers to explore how a human cell responds to a viral attack and whether or not a new candidate drug can prevent the damage caused by that viral infection. The ultimate goal is to deliver screened and validated drugs that can halt disease progression and avoid long-term health consequences.